The abstract is read at the publisher; the summary is JClub's.
Clinical complete response after systemic therapy in muscle-invasive bladder cancer is proposed as a biomarker-like basis for sparing cystectomy in selected patients, pending rigorous validation.
- Why it matters: The field lacks uniform assessments and consistent definitions for clinical complete response, creating uncertainty about whether response-guided treatment can be applied reliably.
- What they did: The work emphasizes treating clinical response assessment with biomarker-level rigor, requiring standardized evaluation methods and clear criteria across studies.
- The result: If future studies confirm reliability, clinical response assessment could enable individualized management that reduces unnecessary cystectomy for appropriately selected muscle-invasive bladder cancer patients.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.